```markdown
---
application_number: 761115Orig1s000
original_submission_date: 2018-05-18
applicant: Immunomedics Inc.
proprietary_name: Trodelvy
product_name: Sacituzumab govitecan
formulation: Powder for solution for infusion
administration_route: Intravenous
concentration: 180 mg
review_outcome: Complete Response - Not Approvable in Present Form
facility_name: Immunomedics, Inc.
facility_location: Morris Plains, NJ
facility_FEI: 1000526871
regulatory_contact:
  name: Jeannette Dinin
  title: Regulatory Project Manager
  phone: (240) 402-4978
  email: Jeannette.Dinin@fda.hhs.gov
signatory:
  name: Richard Pazdur, MD
  title: Acting Director, Office of Hematology & Oncology Products
enclosures:
  - Labeling
  - Carton/Container Labeling
---

## Critical Data

- **Application Number:** 761115Orig1s000  
- **Proprietary Name:** Trodelvy  
- **Nonproprietary Name:** Sacituzumab govitecan  
- **Formulation:** Powder for solution for infusion  
- **Route of Administration:** Intravenous  
- **Strength:** 180 mg  
- **Submission Date:** May 18, 2018  
- **Applicant:** Immunomedics, Inc. (Morris Plains, NJ)  
- **Facility FEI:** 1000526871  
- **Outcome:** Complete Response  
- **Agency Contact:** Jeannette Dinin (Regulatory Project Manager)  
- **Phone:** (240) 402-4978  
- **Email:** Jeannette.Dinin@fda.hhs.gov  
- **Signatory:** Richard Pazdur, MD (Acting Director, OHOP, CDER)  
- **Enclosures:** Labeling, Carton/Container Labeling

---

# CENTER FOR DRUG EVALUATION AND RESEARCH  
## APPLICATION NUMBER: 761115Orig1s000  
## OTHER ACTION LETTERS  

---

## COMPLETE RESPONSE

Please refer to your Biologics License Application (BLA) dated May 18, 2018, and your amendments submitted under section 351(a) of the Public Health Service Act for sacituzumab govitecan powder for solution for infusion, intravenous, 180 mg.

We have completed our review of this application and determined that we cannot approve it in its present form. Below are our reasons and, where possible, recommendations to address these issues.

---

## PRODUCT QUALITY

Per 21 CFR 601.20(c) "No product shall be licensed if any part of the process... would impair the assurances of continued safety, purity, and potency..."

1. **Reference to pre-license inspection at Immunomedics Inc. and Agency communications:**  
   a. Submit information and data to support findings from Form 483 and July 18, 2018 IR.  
   b. Provide evidence supporting findings from October 3, 2018 IR and inspection.

2. Submission must support well-controlled and consistent commercial production. Include root cause analysis and data to confirm consistency.

3. Provide adequate support of testing strategy and implement assay controls as committed in the November 13, 2018 response.

4. Update specifications and submit appropriate data from November 13, 2018 and January 5, 2019 IRs.

5. Provide additional requested information per IR dated November 13, 2018.

6. Additional data required to support stability/manufacturing findings from December 14, 2018 and January 5, 2019 IRs.

7. Address issues related to hRS7 antibody intermediate and IMMU-132 DS.

8. Validation method data requires further clarification and supporting documentation.

9. Reevaluate and support shipping validation studies submitted in response to IR dated November 13, 2018.

---

## PRESCRIBING INFORMATION

Your proposed prescribing information must conform to 21 CFR 201.56(a)-(d) and 201.57.

We encourage review of:

- Final Rule (Physician Labeling Rule)  
- Final Rule (Pregnancy and Lactation Labeling Rule)  
- Related guidance documents  
- Sample formatting tool for Highlights and Contents  
- Selected Requirements for Prescribing Information (SRPI)  
- FDA-approved EPC phrases

Please submit:

- Updated content of labeling in SPL format ([FDA SPL Guidance](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm))
- Marked-up and clean Word versions
- Annotated justifications for changes

---

## CARTON AND CONTAINER LABELING

Submit revised drafts incorporating FDA's proposed revisions.

---

## PROPRIETARY NAME

The name **Trodelvy** was previously found acceptable (August 30, 2018) pending final approval. Resubmit with response package.

---

## FACILITY INSPECTIONS

Objectionable conditions were noted during an inspection of your Morris Plains facility (FEI 1000526871). Satisfactory resolution is required before approval.

---

## SAFETY UPDATE

Submit a comprehensive safety update per 21 CFR 314.50(d)(5)(vi)(b), including:

- New safety data in same format as original submission  
- Retabulated premature discontinuation data  
- Case report forms and narratives for deaths, AEs, SAEs  
- Highlight shifts in frequency of less serious events  
- Updated exposure data and worldwide safety experience  
- English translations of any current approved non-U.S. labeling not previously submitted

---

## ADDITIONAL COMMENTS

### Product Quality

1. Develop a two-tier reference standard system as per ICH Q6B.  
2. Include details from IR dated December 14, 2018.  
3. Acceptance criteria should reflect scientific rationale and study data.

### Immunogenicity

- Unresolved issues must be addressed with sufficient data and information.

### Product Quality Microbiology

- Additional clarification and data required to address outstanding microbiological concerns.

---

## LABELING

For efficacy claims:

- Submit complete BICR evaluation of ORR (cutoff: June 30, 2017)
- Provide DOR based on June 30 and December 1, 2017 cutoffs

---

## OTHER

You must, within one year of this letter:

- Resubmit the BLA, or  
- Take action under 21 CFR 601.3(b)

Failure to do so may result in automatic withdrawal per 21 CFR 601.3(c). You may request an extension.

Resubmission must:

- Address all deficiencies  
- Be clearly marked “RESUBMISSION”  
- Be complete; partial responses will not start a new review cycle

If desired, request a meeting following:  
[Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (Dec 2017)](https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM590547)

**Note:** Product cannot be marketed until final written approval.

---

If you have any questions, contact:

**Jeannette Dinin**  
Regulatory Project Manager  
Phone: (240) 402-4978  
Email: [Jeannette.Dinin@fda.hhs.gov](mailto:Jeannette.Dinin@fda.hhs.gov)

---

Sincerely,  
**RICHARD PAZDUR, MD**  
Acting Director, Office of Hematology & Oncology Products  
Center for Drug Evaluation and Research

---

### ENCLOSURE(S)

- Labeling  
- Carton/Container Labeling  

> 22 Page(s) of Draft Labeling have been Withheld in Full as B4 (CCI/TS)
```